318
Participants
Start Date
April 30, 2010
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
Berinert® (C1 Esterase Inhibitor)
Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
Denmark, Odense C, Odense C
United States, New York, New York
Germany, Berlin, Berlin
United States, New York, North Syracuse
United States, Pennsylvania, Pittsburgh
United States, Pennsylvania, Altoona
United States, Pennsylvania, Hershey
United States, Maryland, Chevy Chase
United States, Maryland, Columbia
United States, North Carolina, Durham
United States, South Carolina, Columbia
United States, Georgia, Atlanta
United States, Ohio, Cincinnati
United States, Ohio, Centerville
Germany, Mainz, Mainz
United States, Minnesota, Plymouth
United States, South Dakota, Rapid City
Germany, Frankfurt, Frankfurt
United States, Missouri, St Louis
United States, Missouri, Kansas City
United States, Louisiana, New Orleans
United States, Oklahoma, Oklahoma City
United States, Oklahoma, Tulsa
United States, Texas, Dallas
Germany, München, München
United States, Idaho, Idaho Falls
United States, Arizona, Scottsdale
United States, New Jersey, Edison
United States, California, Los Angeles
United States, California, Granada Hills
United States, California, San Diego
United States, California, Redding
United States, Oregon, Lake Oswego
United States, Washington, Tacoma
United States, Washington, Spokane
United States, Massachusetts, Boston
United States, New Jersey, Branchburg
United States, New Jersey, Iselin
United States, New Jersey, Ocean City
Switzerland, Luzern 16, Lucerne
Lead Sponsor
Collaborators (1)
Chiltern International Inc.
INDUSTRY
CSL Behring
INDUSTRY